Definitive Contract 75N93021C00040
Award Date
8/1/21
Potential Completion Date
2/29/24
Potential Value
$356K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Avantgen Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
10
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $592,751 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Avantgen Inc., a San Diego-based biotechnology company. The contract is for the development of rabbit monoclonal antibodies to serve as biomarkers for the Indian Flying Fox (bat) virus. There is no set-aside designation for this contract. Avantgen has previously worked with NIAID and other federal agencies on the development of rapid test kits,...
This is a firm fixed-price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), to Ampersand Biosciences LLC, a woman-owned small business. The $599,987 contract is for the development of monoclonal antibodies to chemokines in the ferret model of respiratory disease. The contract is not set aside. Ampersand Biosciences is a biotechnology research company that has received multiple prior NIAID...
This $596,519 fixed-price federal contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Ampersand Biosciences LLC, a woman-owned small business. The contract is for the development of reagents to support immunologic analysis of non-mammalian and underrepresented mammalian models, such as ferrets and mice, under SBIR Topic 107. This aligns with NIAID's mission to conduct and support research to...
The Defense Health Agency awarded a $84,720.53 firm fixed price purchase order to Genovac Antibody Discovery LLC, a small disadvantaged business, for the generation of monoclonal antibodies targeting ferret immunoglobulin M and immunoglobulin G. This requirement was solicited as a 100% small business set-aside. The contract has an ultimate completion date of December 29, 2023 and was awarded on May 1, 2023. The contract was issued under a federal contract opportunity posted on April 7, 2023 with...
This federal contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services (HHS), to Pacific Immunology, a biotech company located in Ramona, California. The $9,996.33 firm fixed price purchase order is for monospecific antibody production services using rabbits. This contract is not set aside for any specific business category. Pacific Immunology has...
The U.S. Department of Health and Human Services (HHS), through the National Institute of Allergy and Infectious Diseases (NIAID), awarded a $5,286.50 firm-fixed-price purchase order to A&G Pharmaceutical, Inc. (doing business as Precision Antibody) for custom antibody generation services. The award, with a completion date of December 18, 2013, is not associated with a set-aside designation. Precision Antibody is a for-profit manufacturer of goods specializing in custom antibody...
Ampersand Biosciences LLC has been awarded a $572,817 firm fixed price contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to develop ferret reagents for use in characterizing immune responses to respiratory infections in the ferret disease model. The contract is associated with the Small Business Innovation Research Program Phase I solicitation and will support the prime contractor's work through August 2022. The total award has been set aside...
This firm fixed price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Geneimmune Biotechnology Corp., a biotechnology company based in Rockville, Maryland. The $31,435.00 contract is for the production of 20 liters of monoclonal antibodies at $1,500 per liter. This award supports NIAID's infectious disease research efforts, leveraging Geneimmune's expertise in areas such as gene...
This firm fixed-price purchase order, valued at $16,215, was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract is for the provision of monoclonal antibodies and plasmids services to support NIAID's biomedical research and public health initiatives. Genscript, a for-profit organization, has received numerous prime...
This is a federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. government, to Abviro LLC, a for-profit limited liability company, on September 19, 2016. The contract is for the development of a broad-spectrum antibody therapeutic against flavivirus infections, with a ceiling value of $29,404,716.25 and a completion date of September 30, 2022. The contract type is a Definitive Contract with a Cost Plus Fixed Fee pricing...